- Home
- PAVM vs ONCO Comparison
PAVM vs ONCO Comparison
Compare PAVM & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- ONCO
- Stock Information
- Founded
- PAVM 2014
- ONCO 2018
- Country
- PAVM United States
- ONCO United States
- Employees
- PAVM N/A
- ONCO N/A
- Industry
- PAVM Medical/Dental Instruments
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- ONCO Health Care
- Exchange
- PAVM Nasdaq
- ONCO Nasdaq
- Market Cap
- PAVM 12.0M
- ONCO 1.8M
- IPO Year
- PAVM 2016
- ONCO 2022
- Fundamental
- Price
- PAVM $0.61
- ONCO $4.70
- Analyst Decision
- PAVM Strong Buy
- ONCO
- Analyst Count
- PAVM 1
- ONCO 0
- Target Price
- PAVM $19.00
- ONCO N/A
- AVG Volume (30 Days)
- PAVM 158.5K
- ONCO 232.8K
- Earning Date
- PAVM 08-11-2025
- ONCO 06-12-2025
- Dividend Yield
- PAVM N/A
- ONCO N/A
- EPS Growth
- PAVM N/A
- ONCO N/A
- EPS
- PAVM 0.96
- ONCO N/A
- Revenue
- PAVM $1,993,000.00
- ONCO $1,925,313.00
- Revenue This Year
- PAVM N/A
- ONCO N/A
- Revenue Next Year
- PAVM $455.63
- ONCO N/A
- P/E Ratio
- PAVM $0.64
- ONCO N/A
- Revenue Growth
- PAVM N/A
- ONCO 153.70
- 52 Week Low
- PAVM $0.55
- ONCO $3.82
- 52 Week High
- PAVM $1.90
- ONCO $1,190.00
- Technical
- Relative Strength Index (RSI)
- PAVM 43.11
- ONCO 42.32
- Support Level
- PAVM $0.59
- ONCO $4.40
- Resistance Level
- PAVM $0.63
- ONCO $5.10
- Average True Range (ATR)
- PAVM 0.04
- ONCO 0.71
- MACD
- PAVM -0.00
- ONCO 0.05
- Stochastic Oscillator
- PAVM 27.06
- ONCO 25.84
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.